UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM6-K
Report of Foreign Private Issuer
Pursuant toRule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the month of January 2018
Commission FileNumber 001-38079
UROGEN PHARMA LTD.
(Translation of registrant’s name into English)
9 Ha’Ta’asiya Street
Ra’anana 4365007, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under coverForm 20-F orForm 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted byRegulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted byRegulation S-T Rule 101(b)(7): ☐
Included as Exhibit 99.1 to this Form6-K is a presentation titled “UroGen Pharma – Changing the Standard of Care for Urothelial Cancers January 2018”, which is incorporated herein by reference. UroGen Pharma Ltd. intends to utilize this presentation in numerous meetings with securities analysts, investors and others in connection with the Annual J.P. Morgan Healthcare Conference which commenced on January 7, 2018.
The information contained in Exhibit 99.1 hereto is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | UroGen Pharma – Changing the Standard of Care for Urothelial Cancers January 2018 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | |
| January 8, 2018 | | | | UROGEN PHARMA LTD. |
| | | |
| | | | By: | | /s/ Gary S. Titus |
| | | | | | Gary S. Titus |
| | | | | | Chief Financial Officer |
